Release issued 30th October 2009

Surveyed neurologists perceive the efficacy of Merck Serono's Rebif nearly as equivalent to that of Biogen Idec's Tysabri, according to a new report from Decision Resources
 
September 30, 2009, Waltham, Mass. - Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that patient-targeted messaging for Emerging Multiple Sclerosis oral agents will need to provide high-level information regarding the efficacy and preservation of quality of life and forego catchy and/or short taglines highlighting oral dosing. The knowledgeable Multiple Sclerosis patient population is likely to already be informed about oral dosing and will want information regarding efficacy and safety so that they can readily compare these new agents to the efficacy and safety of currently available agents.
 
"Based on our survey of Multiple Sclerosis patients, messages from Biogen Idec's Avonex were among the most appealing to patients because they highlight the drug's ability to slow the progression of disability and its ability to reduce the frequency of relapses. Messages highlighting patient support programs (such as Bayer's Betaseron) or needle size (such as Teva Pharmaceutical's Copaxone) were among the least appealing," stated Amanda Puffer, analyst at Decision Resources.
 
The new report entitled Brand Perceptions in Multiple Sclerosis also finds that surveyed neurologists perceive the efficacy of Merck Serono's safer Rebif nearly as equivalent to that of Biogen Idec's Tysabri. Despite Tysabri's efficacy in clinical trials, this shows that neurologists do not perceive its superiority in delaying disability progression to be sufficient to offset its safety drawbacks.
 
"One of our most surprising findings was the fact that surveyed neurologists perceive Tysabri to be only slightly more efficacious than Rebif. Even though Tysabri's efficacy is superior to that of Rebif's, it is well accepted that neurologists are hesitant to prescribe Tysabri because of the risk of Progressive Multifocal Leukoencephalopathy (PML) associated with it," added Ms. Puffer.
 
PML is a rare and potentially fatal central nervous system infection occurring in immune-compromised individuals.
 
The report contains primary research with 101 U.S. neurologists and 253 U.S. patients. Key brands included in the primary research consist of Avonex, Tysabri, Rebif, Betaseron, Copaxone, Genentech's Rituxan, Roche's CellCept and generics.
 
About Brand Perception Series
Decision Resources' Brand Perception Series quantitatively analyzes physician and patient brand perception and message resonance. The findings are driven by extensive primary research and offer clients an unbiased, comprehensive, cost-effective solution to understanding the full competitive brand landscape.

(26th October 2009) Continued uptake of Tnf-Alpha Inhibitors and Interleukin Inhibitors will drive US $2.2 billion growth in the Psoriasis drug market

(22nd October 2009) Tnf-Alpha Inhibitors will continue to dominate first- and second-line Biologic Therapy for the treatment of Rheumatoid Arthritis through 2011

(21st October 2009) Majority of surveyed physicians prescribe Cymbalta and Lyrica for treatment of Fibromyalgia but neither agent has the majority of its uses in first line

(15th October 2009) Sales of Glaxosmithkline’s Relenza likely to increase during the A/H1N1 2009 pandemic as Tamiflu-Resistant Strains of the virus spread

(14th October 2009) Biosimilar Insulins and Insulin Analogues stand to erode US$6.1 billion in brand sales in the U.S. and Europe by 2018